Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Resveratrol triacetate** is a synthetic, acetylated prodrug of resveratrol with increased cell permeability and enhanced stability compared to resveratrol. It is readily hydrolyzed by esterases in vivo to yield active resveratrol. It exhibits similar biological activities to resveratrol, including antioxidant, antitumor, and radioprotective effects. Mechanistically, it can activate p53, increase p21 and p53R2, decrease PSA expression, induce cell cycle arrest, inhibit intracellular melanin synthesis, and interact with integrin αvβ3, among other pathways. Its improved pharmacokinetic properties, such as longer half-life, facilitate more effective delivery of resveratrol to tissues and increased potency in some models[2][7][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on resveratrol triacetate.